Accessibility Menu
 
Nurix Therapeutics logo

Nurix Therapeutics

(NASDAQ) NRIX

Current Price$17.50
Market Cap$1.81B
Since IPO (2020)-8%
5 Year-40%
1 Year+71%
1 Month+16%

Nurix Therapeutics Financials at a Glance

Market Cap

$1.81B

Revenue (TTM)

$71.78M

Net Income (TTM)

$295.28M

EPS (TTM)

$-3.16

P/E Ratio

-5.54

Dividend

$0.00

Beta (Volatility)

1.55 (High)

Price

$17.50

Volume

34,696

Open

$17.24

Previous Close

$17.50

Daily Range

$16.93 - $17.68

52-Week Range

$8.20 - $22.50

NRIX: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nurix Therapeutics

Industry

Biotechnology

Employees

317

CEO

Arthur T. Sands, MD, PhD

Headquarters

San Francisco, CA 94158, US

NRIX Financials

Key Financial Metrics (TTM)

Gross Margin

-1%

Operating Margin

-4%

Net Income Margin

-4%

Return on Equity

-61%

Return on Capital

-58%

Return on Assets

-46%

Earnings Yield

-18.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.81B

Shares Outstanding

103.41M

Volume

34.70K

Short Interest

0.00%

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

$65.12M

Operating Income

$285.67M

EBITDA

$244.84M

Operating Cash Flow

$249.47M

Capital Expenditure

$14.00M

Free Cash Flow

$263.47M

Cash & ST Invst.

$592.94M

Total Debt

$55.73M

Nurix Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.25M

-66.1%

Gross Profit

$77.89M

-52.1%

Gross Margin

-12.46%

N/A

Market Cap

$1.81B

N/A

Market Cap/Employee

$6.33M

N/A

Employees

286

N/A

Net Income

$87.17M

-54.7%

EBITDA

$92.50M

-52.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$482.08M

-7.8%

Accounts Receivable

$2.40M

N/A

Inventory

$0.00

N/A

Long Term Debt

$55.45M

+177.5%

Short Term Debt

$3.20M

-51.8%

Return on Assets

-46.42%

N/A

Return on Invested Capital

-57.97%

N/A

Free Cash Flow

$72.96M

-13.0%

Operating Cash Flow

$71.91M

-17.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EYPTEyePoint Pharmaceuticals, Inc.
$14.93+0.81%
KODKodiak Sciences Inc.
$44.90+11.11%
SEPNSepterna, Inc.
$26.13+4.56%
URGNUroGen Pharma Ltd.
$22.54+5.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
EFOIEnergy Focus
$6.49+2.11%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.90+0.06%
INTCIntel
$68.50+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$58.59+0.04%

Questions About NRIX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.